The Saving Our Children Campaign Launches in Southern 15-02-2023, 05:23

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

IEDC to Target Semiconductor Innovation and Launch New Taiwan Office 3-09-2024, 22:10